The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials

Author(s): Solomon, BJ; de Castro, G, Jr; Tan, DSW; Butler, AA; Cobo, M; Garassino, MC; Zhang, J; Johnson, BE; Lee, JM; Garrido, P; Pelletier, MR; Savchenko, A; Ji, L; Brase, JC; Caparica, R; Demanse, D; Wu, J; Bossen, C; Mok, T;
Details: Publication Year 2025-04-01,Volume 5,Issue #4,Page 632-646
Journal Title: Cancer Research Communications
Publication Type: Research article
Abstract: Patients with NSCLC with immunosuppressive tumor features and low T-cell infiltration derive less benefit from ICI-based treatment. Biomarker analyses presented here suggest that these patients may benefit from the addition of anti-IL-1β therapy to their treatment.
Publisher: American Association for Cancer Research
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/pathology; *Lung Neoplasms/drug therapy/immunology/pathology; *Tumor Microenvironment/drug effects/immunology; *Interleukin-1beta/antagonists & inhibitors; *Biomarkers, Tumor/metabolism; Immune Checkpoint Inhibitors/therapeutic use
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1158/2767-9764.Crc-24-0490
Open Access at Publisher's Site: https://doi.org/10.1158/2767-9764.Crc-24-0490
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-04-10 01:21:57

Last Modified: 2025-07-08 04:31:30